AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study
23 Jan 2024
Clinical ResultPhase 3ASCOImmunotherapyDrug Approval
Preview
Source: PMLiVE
AstraZeneca (AZ) has shared positive results from a late-stage study evaluating its immunotherapy Imfinzi (durvalumab) in a subset of patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.
The phase 3 EMERALD-1 trial has been comparing Imfinzi plus transarterial chemoembolisation (TACE), followed by Imfinzi with or without Genentech’s Avastin (bevacizumab), until progression against TACE alone in more than 600 patients with unresectable HCC eligible for embolisation.
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation, a procedure that blocks blood supply to the tumour and can also deliver chemotherapy or radiation therapy directly to the liver.
Despite being the standard of care in this setting, AZ outlined that most patients who receive embolisation experience rapid disease progression or recurrence.
According to the results from EMERALD-1, which were presented at this year’s American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Imfinzi in combination with TACE and Avastin reduced the risk of disease progression or death by 23% compared to TACE alone.
The company added that the secondary endpoint of time to progression "further supports the clinical benefit" of the Imfinzi combination in this setting, at a median of 22 months versus ten months for TACE. The trial will continue to follow the key secondary endpoint of overall survival.
Susan Galbraith, executive vice president, oncology research and development, AZ, said: "With Imfinzi-based treatment, patients with liver cancer eligible for embolisation lived nearly seven additional months before their disease progressed.
“We are discussing these positive EMERALD-1 data with global regulatory authorities while awaiting the final overall survival results from the trial.”
Imfinzi is already approved in combination with AZ's Imjudo (tremelimumab) in unresectable HCC in the US, EU, Japan and other countries worldwide.
Lead investigator in EMERALD-1, Bruno Sangro, from Clínica Universidad de Navarra in Spain, said: “Adding [Imfinzi] and [Avastin] to TACE reduced the risk of disease progression or death by 23% for patients with liver cancer eligible for embolisation, showing for the first time that combining a systemic treatment with TACE meaningfully improves this clinically relevant outcome in earlier-stage disease.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.